ONLINE SUBMISSION
  September, 2010

Gliosarcoma: a rare variant of glioblastoma multiforme

  Sadia Rizvi, Asghar Hussain Asghar  ( Department of Clinical Oncology, KIRAN Hospital, Karachi, Pakistan. )
Javaid Mehboob  ( Department of Radiology, KIRAN Hospital, Karachi, Pakistan. )
 

Abstract

Gliosarcoma is a rare variant of Glioblastoma Multiforme (GBM). It is a very aggressive tumour and usually managed like GBM. Treatment of choice is surgery with good surgical margins followed by radiotherapy (60 Gy). Median survival is seven months. Here we present a case report of 55 years old male who was diagnosed as brain tumour in left temporoparietal region. It turned out to be gliosarcoma after surgical resection and histopathological evaluation.


Introduction

Gliosarcoma is a rare variant of Glioblastoma Multiforme (GBM). It contains both glial and sarcomatous component. Epidemiology and natural history of this tumour is ill defined. It usually affects 5th and 6th decade of life with slight male preponderance.1 Surveillance, Epidemiology and End Results (SEER) database reveals only 2.2% of gliosarcoma out of 16,388 patients identified with either gliosarcoma or GBM from 1988-2004. Most of them had involvement of temporal lobe.2 Exact cause is unknown but may be radiaton induced. Mean survival is 13 months (6.9-19.4 months).3 It has a propensity for distant metastasis and usual site of involvement is lung followed by liver and bone.4 Here we present a case report of 55 years old male who presented with space occupying lesion (SOL) in brain which turned out to be Gliosarcoma after surgical resection and histopathological evaluation.


Case Report

Fifty five years old male resident of Nawabshah was normotensive and normoglycemic. He presented with history of headache more on left side, dysarthria, vomiting and right sided hemiparesis for the last five months. It was not associated with any history of fits, visual disturbances, fever or loss of consciousness. He consulted a physician is his hometown who advised a CT scan brain. CT brain was done on January 22, 2009. It revealed a mass having mixed cystic and solid component in left temporoparietal region (Figure-1).

He was referred to a neurosurgeon who performed a craniotomy and drained the cystic fluid. Unfortunately, histopathological examination was not done. Patient remained stable for two months after surgery without any adjuvant treatment. Immediate postoperative MRI was also not done. His symptoms improved significantly after surgery. However, he developed same headache and dysarthria after two months of surgery. Again CT scan brain was advised in March 2009 which revealed a recurrent/residual mass in the same region. The second surgery was performed on May 19, 2009. Histopathology revealed Gliosarcoma. Immunohistochemistry showed positive staining for Glial Fibrillary Acid Protein (GFAP) and Vimentin. After this second surgery, he was referred to our hospital for further management. Here he was thoroughly evaluated for any distant metastases and fresh MRI was advised to rule out any residual disease. Unfortunately, he was still having a residual mass in the same left temporoparietal region (Figure-2).

There were no distant metastases. Patient’s general condition was stable. He was fully conscious and well oriented to time and space. ECOG (Eastern Cooperative Oncology Group) performance status was one. His craniotomy scar mark was healed and vision was normal. We planned for concurrent chemoradiation with Temozolomide but due to financial problem, he refused Temozolomide. Therefore, he was planned for radiation alone. He received 60 Gy in 30 fractions with 3D conformal technique over a period of 40 days along with steroids. He completed his course of radiotherapy successfully and remained symptoms free for three months. He then developed right sided hemiparesis, headache, vomiting and loss of consciousness. His general condition deteriorated rapidly, and was shifted to tertiary care hospital where supportive treatment was started. He remained on supportive treatment for two weeks and expired within nine months of diagnosis.


Discussion

Gliosarcoma is a rare brain tumour and represents 2% of GBM. It is usually diagnosed and treated like GBM. Single institutional data from Germany published in 2009 revealed only 16 patients treated over a period of 10 years (1997-2006).5 Another audit from an institute of India published in 2008 presents only 24 patients of gliosarcoma as compared to 251 cases of GBM treated over a period of 15 years (1990-2004).6 Local data revealed 16 cases of gliosarcoma reported from pathology department of Aga Khan University hospital in 2004.7 Recently another case has been reported in local journal of Pakistan.8 There are fewer than 20 reported cases of extracranial metastases of gliosarcoma with majority of them reflecting a tendency for haematogenous dissemination.


References

1.di Norcia V, Piccirilli M, Giangaspero F, Salvati M. Gliosarcomas in the elderly: analysis of 7 cases and clinico-pathological remarks. Tumori 2008; 94: 493-6.
2.Kozak KR, Mahadevan A, Moody JS. Adult gliosarcoma: epidemiology, natural history and factors associated with outcome. Neuro Oncol 2009; 11: 183-91.
3.Han SJ, Yang I, Tihan T, Chang SM, Parsa AT. Secondary Gliosarcoma: a review of clinical features and pathological diagnosis. J Neurosurg 2010; 112: 26-32.
4.Beaumont TL, Kupsky WJ, Barger GR, Sloan AE. Gliosarcoma with multiple extracranial metastases: case report and review of literature. J Neurooncol 2007; 83: 39-46.
5.Buhl R, Stark AM, Hugo HH, Rohr A, Mehdorn HM. Gliosarcoma: clinical experiences and additional information with MR spectroscopy. Neurol Res 2009; 31: 873-7.
6.Kumar P, Singh S, Kumar P, Krishnani N, Datta NR. Gliosarcoma: an audit from a single institution in India of 24 post-irradiated cases over 15 years. J Cancer Res Ther 2008; 4: 164-8.
7.Ahmed Z, Azad NS, Muzaffer S, Nasir I, Hasan S. CNS tumors at AKU: an update plus a brief discussion on Intraventricular Tumors with special emphasis on Central Neurocytoma. J Ayub Med Coll Abbottabad 2004; 16: 12-5.
8.Cincu R, Lazaro JFM, Liesa JLC, Eiras J. Gliosarcoma: An uncommon brain tumor. Pak J Neurol Sci 2009; 4: 20-2.


News & Events

Dear Friends and Colleagues,
May you have a very Happy EID with your friends and Family.
May all of us be Blessed with peace and tranquility.
Let us all jointly say a prayer for all troubled persons all over the world
Warm regards,
Dr. Fatema Jawad
Editor-in-chief,
Journal of Pakistan Medical Association, Karachi
President, PAME
Pakistan Association of Medical Editors



WHO/GOARN Request for technical assistance for Cholera Control in Northern Iraq

Request for assistance

WHO is requesting assistance from GOARN partners to identify the following cholera and diarrhoeal diseases expertise to support the Ministry of Health of Iraq in cholera risk assessment and immediate preparedness activities to improve the health outcomes of the Syrian refugees current living in camps in the Kurdistan region of Iraq.

  • two (2) epidemiologists
  • two (2) clinical management experts
  • one (1) environmental health expert (WATSAN)
  • one (1)laboratory expert

Duration

6 day mission starting 13 June 2014 (this excludes travel time).

Location

Northern Iraq (Kurdistan region).

Language requirements

All candidates must be fluent in English- written, spoken and comprehension. Fluency in Arabic is an asset. Knowledge, abilities and skills All candidates are expected to demonstrate the following

  • Ability to conceptualize and promote innovative strategies and policies.
  • Ability to communicate and write in a clear concise manner, and to develop effective guidelines.
  • Excellent negotiation and interpersonal skills complemented by ability to motivate and lead others and to promote consensus. Tact, discretion and diplomacy
  • Demonstrated ability for project appraisal, project management, monitoring and evaluation and project impact assessment.
  • Ability to work with host governments and their agents, INGOs and national NGOs an advantage.
  • Proven experience of managing a large workload and multiple priorities.
  • Ability to work in difficult conditions.

Support to the mission

WHO/GOARN will cover the travel and per diem (to cover daily expense in the field) expenses for the duration of their mission. GOARN missions do NOT offer salary, consultancy fees or any other form of remuneration.

WHO will provide appropriate logistics support for the field mission. Pre-deployment orientation/training may be required at WHO.

Partners offers of assistance

Partners are requested to reply with offers of assistance, together with CVs and details of the availability of staff for this mission by email to goarn@who.int latest by 30 May 2014. Details of all offers from partners and eventual deployments will be maintained on the GOARN SharePoint.

Operational Contacts

Mamunur Malik WHO EMRO malikm@who.int

William Perea WHO HQ pereaw@who.int

Patrick Drury GOARN druryp@who.int



News



Index



Supplement